DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer

DNA Repair

Volumn 40, Issue , 2016, Pages 35-46

  Sears, Catherine R ^a   Cooney, Sean A ^b   Chin Sinex, Helen ^a   Mendonca, Marc S ^a   Turchi, John J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

ATM; ATR; Cisplatin; Damage response; Lung cancer; Radiation

Indexed keywords

ATM PROTEIN; BIOLOGICAL MARKER; CISPLATIN; HISTONE H2AX; PHOSPHOTRANSFERASE; ANTINEOPLASTIC AGENT; DNA LIGASE; RADIOSENSITIZING AGENT;

ARTICLE; CHEMORADIOTHERAPY; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IONIZING RADIATION; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RADIOSENSITIZATION; DRUG EFFECTS; GENETICS; METABOLISM; RADIATION TOLERANCE; RECOMBINATION REPAIR; TUMOR CELL LINE; X RAY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR ENZYMES; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECOMBINATIONAL DNA REPAIR; X-RAYS;

EID: 84960935094     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2016.02.004     Document Type: Article

References (53)

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65:5-29. 10.3322/caac.21254.
2. Wakelee H.A., Bernardo P., Johnson D.H., Schiller J.H. Changes in the natural history of nonsmall cell lung cancer (NSCLC)-comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer 2006, 106:2208-2217. 10.1002/cncr.21869.
3. Jett J.R., Schild S.E., Keith R.L., Kesler K.A. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007, 132:266S-276S. 10.1378/chest.07-1380.
4. Stinchcombe T.E., Socinski M.A. Current treatments for advanced stage non-small cell lung cancer. Proc. Am. Thorac. Soc. 2009, 6:233-241. 10.1513/pats.200809-110LC.
5. O'Rourke N., Roqué i Figuls M., Farré Bernadó N., Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst. Rev. 2010, 3. (Art. No.: CD002140). 10.1002/14651858.
6. Auperin A., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:2181-2190. 10.1200/jco.2009.26.2543.
7. Groen H. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. Br. J. Cancer 1995, 140:6-1411.
8. Curran W.J., et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J. Natl. Cancer Inst. 2011, 103:1452-1460. 10.1093/jnci/djr325.
9. Dolling J.-A., Boreham D.R., Brown D.L., Raaphorst G.P., Mitchel R.E.J. Cisplatin-modifications of DNA repair and ionizing radiation lethality in yeast, Saccharomyces cerevisiae. Mutat. Res. 1999, 433:127-136.
10. Toulany M., Mihatsch J., Holler M., Chaachouay H., Rodemann H.P. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition. Radiother. Oncol. 2014, 111:228-236. 10.1016/j.radonc.2014.04.001.
11. Sakai W., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120. 10.1038/nature06633.
12. Kartalou M., Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 2001, 478:23-43.
13. McKay B.C., Becerril C., Ljungman M. P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. Oncogene 2001, 20:6805-6808.
14. Koberle B., Masters J.R.W., Hartley J.A., Wood R.D. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumors. Curr. Biol. 1999, 9:273-276.
15. Ho K.S.Y. Induction of DNA double-strand breaks by X-rays in a radiosensitive strain of the yeast Saccharomyces Cerevisiae. Mutat. Res. 1975, 30:327-334.
16. Jeggo P., Lavin M.F. Cellular radiosensitivity: how much better do we understand it?. Int. J. Radiat. Biol. 2009, 85:1061-1081. 10.3109/09553000903261263.
17. Boeckman H.J., Trego K.S., Turchi J.J. Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol. Cancer Res. 2005, 3:277-285. 10.1158/1541-7786.mcr-04-0032.
18. Rogakou E.P., Pilch A.H., Ivanova V.S., Bonner, WM DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 1998, 273:5858-5868.
19. Olive P.L., Banath J.P. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin. Cytom. 2009, 76:79-90. 10.1002/cyto.b.20450.
20. Sedelnikova O.A., Rogakou E.P., Panyutin I.G., Bonner W.M. Quantitative detection of 125IdU-Induced DNA double-strand breaks with γ-H2AX. Antibody Radiat. Res. 2002, 158:486-492. (158[0486:qdoiid]2.0.co;2). 10.1667/0033-7587.
21. Woods D., Turchi J. J. Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol. Ther. 2013, 14:379-389. 10.4161/cbt.23761.
22. Ahmad S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem. Biodivers. 2010, 7:543-565.
23. Huntoon C.J., et al. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013, 73:3683-3691. 10.1158/0008-5472.CAN-13-0110.
24. Hall A.B., et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget 2014, 5:5674-5685.
25. Hickson I., et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004, 64:9152-9159.
26. Taccioli G.E., et al. Targeted disruption of the catalytic subunit of the DNA-PK gene in mice confers severe combined immunodeficiency and radiosensitivity. Immunity 1998, 9:355-366.
27. Rosenzweig K.E., Youmell M.B., Palayoor S.T., Price B.D. Radiosensitization of human tumor cells by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolongued G2-M delay. Clin. Cancer Res. 1997, 3:1149-1156.
28. Myint W.K., Cheng N.G., Raaphorst G.P. Examining the non-homologous repair process following cisplatin and radiation treatments. Int. J. Radiat. Biol. 2002, 78:417-424. 10.1080/0955300011011304.
29. Raaphorst G., LeBlanc J.-M., Li L.F. A comparison of response to cisplatin, radiation and combined treatment for cells deficient in recombination repair pathways. Anticancer Res. 2005, 25:53-58.
30. Sears C.R., Turchi J. J. Complex cisplatin-double strand break (DSB) lesions directly impair cellular non-homologous end-joining (NHEJ) independent of downstream damage response (DDR) pathways. J. Biol. Chem. 2012, 287:24263-24272. 10.1074/jbc.M112.344911.
31. Diggle C.P. Inhibition of double-strand break non-homologous end-joining by cisplatin adducts in human cell extracts. Nucleic Acids Res. 2005, 33:2531-2539. 10.1093/nar/gki528.
32. Mendonca M.S., et al. Differential mechanisms of x-ray-induced cell death in human endothelial progenitor cells isolated from cord blood and adults. Radiat. Res. 2011, 176:208-216.
33. Stiff T., et al. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 2004, 64:2390-2396.
34. Byun J., et al. Automated tool for the detection of cell nuclei in digital microscopic images: application to retinal images. Mol. Vis. 2006, 2006.
35. Revet I., et al. Functional relevance of the histone gammaH2Ax in the response to DNA damaging agents. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:8663-8667. 10.1073/pnas.1105866108.
36. Maity A., McKenna W.G., Muschel R.J. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother. Oncol. 1994, 31:1-13.
37. Almeida G.M., Duarte T.L., Farmer P.B., Steward W.P., Jones G.D.D. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: Implications for predictive testing. Int. J. Cancer 2008, 122:1810-1819. 10.1002/ijc.23188.
38. Fujikane T., et al. Flow cytometric analysis of the kinetic effects of cisplatin on lung cancer cells. Cytometry 1989, 10:788-795.
39. Shaheen F.S., et al. Targeting the DNA double strand break repair machinery in prostate cancer. PLoS One 2011, 6:e20311. 10.1371/journal.pone.0020311.
40. Ashley A.K., et al. DNA-PK phosphorylation of RPA32 Ser4/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe. DNA Repair 2014, 21:131-139. 10.1016/j.dnarep.2014.04.008.
41. Fokas E., et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012, 3:e441. 10.1038/cddis.2012.181.
42. Reaper P.M., et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011, 7:428-430. 10.1038/nchembio.573.
43. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271. 10.1378/chest.08-0978.
44. Turchi J.J., Henkels K.M. Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase. J. Biol. Chem. 1996, 271:13861-13867.
45. Turchi J.J., Henkels K.M., Zhou Y. Cisplatin-DNA adducts inhibit translocation subunits of DNA-PK. Nucleic Acids Res. 2000, 28:4634-4641.
46. Sak A., et al. Long-term in vivo effects of cisplatin on γ-H2AX foci signaling in peripheral lymphocytes of tumor patients after irradiation. Clin. Cancer Res. 2009, 15:2927-2934. 10.1158/1078-0432.ccr-08-0650.
47. Banuelos C.A., Banath J.P., Kim J.Y., Aquino-Parsons C., Olive P.L. GammaH2AX expression in tumors exposed to cisplatin and fractionated irradiation. Clin. Cancer Res. 2009, 15:3344-3353. 10.1158/1078-0432.CCR-08-3114.
48. Klokov D., MacPhail S.M., Banath J.P., Byrne J.P., Olive P.L. Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. Radiother. Oncol. 2006, 80:223-229. 10.1016/j.radonc.2006.07.026.
49. Mascharak P.K., Sugiura Y., Kuwahara J., Suzuki T., Lippard S.J. Alteration and activation of sequence-specific cleavage of DNA by bleomycin in the presence of the antitumor drug cis-diamminedichloroplatinum(II). Proc. Natl. Acad. Sci. U. S. A. 1983, 80:6795-6798.
50. Vràna O., Brabec V. The effect of combined treatment with platinum complexes and ionizing radiation on DNA in vitro. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 1986, 50:995-1007.
51. Rezaee M., Sanche L., Hunting D.J. Cisplatin enhances the formation of DNA single- and double-strand breaks by hydrated electrons and hydroxyl radicals. Radiat. Res. 2013, 179:323-331. 10.1667/RR3185.1.
52. Kouass Sahbani S., Rezaee M., Cloutier P., Sanche L., Hunting D.J. Non-DSB clustered DNA lesions induced by ionizing radiation are largely responsible for the loss of plasmid DNA functionality in the presence of cisplatin. Chem. Biol. Interact. 2014, 217:9-18. 10.1016/j.cbi.2014.04.004.
53. Prevo R., et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol. Ther. 2012, 13:1072-1081. 10.4161/cbt.21093.